Dupilumab
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Eosinophilic Esophagitis
Conditions
Eosinophilic Esophagitis, EoE
Trial Timeline
May 16, 2024 → Dec 1, 2026
NCT ID
NCT06352073About Dupilumab
Dupilumab is a approved stage product being developed by Sanofi for Eosinophilic Esophagitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06352073. Target conditions include Eosinophilic Esophagitis, EoE.
What happened to similar drugs?
5 of 16 similar drugs in Eosinophilic Esophagitis were approved
Approved (5) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05906706 | Pre-clinical | Completed |
| NCT07316114 | Pre-clinical | Recruiting |
| NCT07467564 | Pre-clinical | Recruiting |
| NCT07187089 | Approved | Withdrawn |
| NCT07112378 | Phase 3 | Recruiting |
| NCT07052396 | Pre-clinical | Recruiting |
| NCT07276425 | Pre-clinical | Recruiting |
| NCT06695897 | Pre-clinical | Recruiting |
| NCT06693531 | Pre-clinical | Recruiting |
| NCT06415175 | Pre-clinical | Active |
| NCT06556264 | Approved | Recruiting |
| NCT06352073 | Approved | Recruiting |
| NCT06293053 | Phase 3 | Recruiting |
| NCT05983068 | Approved | Active |
| NCT06234761 | Pre-clinical | Recruiting |
| NCT05991323 | Pre-clinical | Active |
| NCT06192563 | Pre-clinical | Recruiting |
| NCT06169527 | Pre-clinical | Active |
| NCT06393946 | Pre-clinical | Active |
| NCT05831176 | Phase 2 | Active |
Competing Products
20 competing products in Eosinophilic Esophagitis